Abstract: Objective :To observe the clinical and adverse effect of gemcitabine plus docetaxel,the non-platinum agents,in treatment on non-small cell lung cancer(NSCLC). Methods :Gemcitabine(1000mg/m²,d1,d8)plus docetaxel(75mg/m²,iv drop,d1)were administered to 43 patients,IV drop 30min,with 28d a cycle and for 2 cycles of treatment at least. Results :Three patients discontinued because of treatment-related adverse effects,so the forty patients were estimated at last.The overall response rate was 35%.Median survival time and the median time for progression of disease(TTP)was 10 months and 7.2 months,and the 1-year and 2-year survival rate was 37.5% and 12.5%,respectively.The main adverse effect was myelo-suppression(or =Grade III)and leukopenia(32.5%).No nausea and vomiting of grade III/IV were found.Other toxicities were mild.All adverse effects were tolerated by sustaining therapy and allopathy. Conclusion :Gemcitabine plus docetaxel is an active and well-tolerated regimen and represents an option for treatment of the patients with advanced NSCLC.It will be of significance for enhancement of quality of life and extension of life span and can be used as an effective regimen to substitute the platinum drugs.